Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 78Osteosarcoma 34Melanoma 22Sarcoma, Ewing 20Neuroblastoma 19Rhabdomyosarcoma 17Ovarian Neoplasms 17Gastrointestinal Stromal Tumors 17Colorectal Neoplasms 16Glioblastoma 15Bone Neoplasms 15Sarcoma, Kaposi 14Rhabdoid Tumor 14Neoplasms 14Breast Neoplasms 14Wilms Tumor 13Liposarcoma 13Neoplasm Metastasis 12Gliosarcoma 12Medulloblastoma 11Lymphoma, Non-Hodgkin 11Hepatoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 10Neurofibrosarcoma 10Thyroid Neoplasms 9Recurrence 9Pancreatic Neoplasms 9Ependymoma 9

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Sarcoma × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡